Pipeline

SCY001P

Scythian’s first patent application covers a two-drug combination therapy for concussive treatment. That is, the combined use of an NMDA antagonist plus a CB2 agonist, either cannabinoid or non-cannabinoid.

SCY002P

Scythian’s second patent filing covers methods and compositions for treating gastrointestinal inflammation. This includes the use of the cannabinoid CBD, the same CB-2 agonist covered in our concussion treatment combination, together with an NMDA receptor or FAAH inhibitor to control intestinal inflammation.